China NMPA Inspection - Liuzhou Liangmianzhen Co., Ltd. - November 28, 2019

The Guangxi Zhuang Autonomous Region Drug Administration conducted supervisory inspections of multiple licensed cosmetics manufacturers in the region as part of its 2019 work plan. The inspections, primarily occurring in November 2019, aimed to strengthen supervision over cosmetics production. The regulatory framework for these assessments was based on the "Key Points for Inspection of Cosmetics Production License."Among the companies inspected, Guangxi Falao Biotechnology Co., Ltd. faced significant findings during its October 9, 2019 inspection. Key violations included serious issues such as inadequate traceability for raw materials in batch production records, a lack of essential laboratory equipment for specific quality control tests (e.g., temperature control for cold resistance), and an unreasonable logistics flow between production areas, posing a clear risk of cross-contamination.Further general defects at Guangxi Falao included insufficient production personnel, discrepancies between raw material quality standards and actual usage, incomplete microbial experiment records, and a lack of supplier traceability for key raw materials. Additionally, raw material labeling in storage was found to be non-compliant, and retained sample management was inadequate, with incomplete batch production records.For Guangxi Falao Biotechnology Co., Ltd. and other companies with identified defects like Guangxi Yaozhi Yupin Trading Co., Ltd. (which had issues with equipment status, material cards, and storage separation), the administration mandated prompt rectification of all noted deficiencies within a specified timeframe. Companies are required to submit a comprehensive rectification report upon completion to the Guangxi Zhuang Autonomous Region Drug Administration. In contrast, Liuzhou Liangmianzhen Co., Ltd. had a minor labeling issue that was rectified on-site.